enGene Holdings (NASDAQ: ENGN) announced the appointment of Amy Pott as chief global commercialization officer—the company’s first dedicated executive for commercialization endeavors—reporting to Ron Cooper, CEO of enGene.
Ms. Pott joins enGene from Astellas Pharma, where she served as SVP, strategic brand marketing, ophthalmics and rare diseases, and previously as head of commercial, gene therapies.
According to enGene, the appointment marks a significant milestone, as the company expects to file a Biologics License Application (BLA) with the FDA in mid-2026 for detalimogene voraplasmid, its lead investigational agent in Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC), following the completion of the pivotal cohort of the LEGEND trial.
“Amy brings a unique combination of P&L, full commercialization, gene therapy, deep analytics, and global experience to enGene,” said Mr. Cooper. “We are thrilled to welcome Amy as our chief global commercialization officer and believe her leadership and track record of success will be a tremendous asset in preparing and executing the planned launch of detalimogene.”
Ms. Pott remarked, “I am excited to join enGene at such a pivotal moment in its journey. I look forward to working with this talented team to advance the mission to help transform the treatment landscape for bladder cancer patients with our innovative genetic medicine.”
